LDS/Medical Tests/Heparin Cofactor II

Heparin Cofactor II

Fractionated heparin is a polysaccharide that inhibits coagulation of blood when present. Heparin is routinely prescribed to patients who are at risk for forming blood clots or thrombosis. Low-molecular weight heparin (LMWH) is now available. It has many benefits over unfractionated heparin (UH) such as one daily dose, lower risk of osteoporosis, lower risk of Heparin Induced Thrombocytopenia, and it can be prescribed to outpatients. Therapeutic doses of heparin require close laboratory monitoring because metabolizing the drug depends on the capability of liver enzymes. The activated partial thromboplastin time (aPTT) is the usual test of choice for monitoring unfractionated heparin therapy. However, when present at therapeutic levels, low-molecular weight heparin (LMWH) usually does not prolong the activated Partial Thromboplastin Time (aPTT). The Anti-Xa activity of heparin is not affected by the molecular weight of the heparin. The anti-Xa assay is a more appropriate chromogenic assay that measures the LMWH level indirectly. It should be noted that the anti-Xa assay measures both unfractionated and low molecular weight heparin.  In fact, the anti-Xa assay is not affected by acute phase reactants and factor deficiencies other than antithrombin deficiency.  The term "anti-Xa" may be confusing. Heparins act to inhibit Factor X by acting in combination with antithrombin III. Thus, the more heparin in a specimen, the less activated Factor X (Xa) is left for the chromogenic part of the assay. So increasing values of the "Anti-Xa" test reflect increasing levels of heparin in the patient specimen (heparin being the "anti" component). Increasing values of the anti-Xa test indicate increasing anticoagulation (more heparin). Low values indicate low anticoagulation (less heparin). Low molecular weight heparin is contraindicated in renal failure patients due to the renal clearance of the drug.

  • Monitoring low-molecular weight heparin (LMWH) therapy
  • Monitoring danaparoid therapy
  • Evaluation of prolonged aPTT
  • To evaluate conditions in which more unfractionated heparin than usual is needed to prolong the aPTT

Increased in:

  • Renal failure
  • Specimen contaminated with heparin

Decreased in:

  • Specimen collection at inappropriate time
  • Delay is separating plasma from cells
  • Specimen stored inappropriately or specimen transport longer than 2 hours
  • Incorrect treatment
  • Patient received preventative dose and not full dose

No heparin: <0.05 U/mL
Therapeutic Heparin: 0.3-0.7 U/mL

Chromogenic method (indirectly) that is measured Spectrophotometric.

Plasma Citrate (Light Blue). 

Separate Plasma and freeze immediately. Maintain frozen until testing.

Sodium citrate blue top tube collected four hours post dose for LMWH or six hours post dose for Danaparoid. Double spin and freeze plasma for transport.

Note: Separate plasma from cells within one hour of collection as platelets release PF4 which is a heparin inhibitor.

Stability

  • Ambient: Unacceptable
  • Refrigerated: Unacceptable
  • Frozen: 30 days
Activated Clotting Time (ACT), Activated Partial Thromboplastin Time (aPTT), Antithrombin, Thrombin Time, Heparin Antibodies.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Semin Thromb Hemost. 2011 Sep;37(6):653-63. [PMID: 22102268]
  • Am Clin Lab. 2001 Aug;20(7):35-8. [PMID: 11570272]
  • Blood Coagul Fibrinolysis. 2005;16:173. [PMID: 15795534]
  • Am J Clin Pathol. 2006;126:416. [PMID: 16880140]
  • Br J Haematol. 2006;133:19. [PMID: 16512825]
  • Jacobs DS, DeMott WR. Laboratory test handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
  • George Fritsma, KD. Hematology, Clinical Principles and Applications, Third Edition. St. Louis: Saunders Elsevier (2007).